UKALL14 sub study

 Acute lymphoblastic leukaemia (ALL) / Posted 1 year ago

The UKALL14 trial is looking at different treatments for ALL.

The team would now like to do a sub study to find out more about the genes of the leukaemic cells. They also want to find out more about whether they can predict how well treatment will work based on these changes.

In this study you have the standard chemotherapy treatment for ALL at your hospital. The study team will ask for small amount of your bone marrow sample Open a glossary item that is taken before starting your treatment.

They are looking for a substance (biomarker Open a glossary item) in the sample they can use to follow how well your leukaemia responds to treatment. They are also looking for any gene changes in the cells of your leukaemia.

  • Inclusion Criteria :
    • have recently been diagnosed with acute lymphoblastic leukaemia (ALL) and have not yet had any treatment apart from steroids
    • are between 25 and 65 years old (inclusive) or
    • you are between 19 and 65 and you have ALL with the Philadelphia chromosome
  • Exclusion Criteria :
    • have a mature B cell leukaemia such as Burkitt type ALL
    • are in the blast transformation stage
    • have chronic myeloid leukaemia (CML)
    • are known to be HIV positive
    • are known to have hepatitis B or hepatitis C
    • are pregnant or breastfeeding
  • Study start date : 01/12/2017
  • Study end date : 31/12/2020
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Professor Adele Fielding

No post found